1 / 3

PD-1/PD-L1 임상개발 비교표

PD-1/PD-L1 임상개발 비교표. October, 2014. Clinical Trials for NSCLC (P3 Only). *+Gemcitabine + cisplatin + carboplatin + paclitaxel + pemetrexed (investigators’ choice chemo) ** carboplatin + paclitaxel + pemetrexed

rahim-foreman
Download Presentation

PD-1/PD-L1 임상개발 비교표

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. PD-1/PD-L1 임상개발 비교표 October, 2014

  2. Clinical Trials for NSCLC (P3 Only) *+Gemcitabine + cisplatin + carboplatin + paclitaxel + pemetrexed (investigators’ choice chemo) ** carboplatin + paclitaxel + pemetrexed *** (pemetrexed+ carboplatin) or (pemetrexed + cisplatin) or (gemcitabine + carboplatin) or (gemcitabine + cisplatin)

  3. Clinical Trials for Melanoma (P3/P2 Only) * Dacarbazien or (carboplatin + paclitaxel) ** dabrafenib(BRAFT inhibitor) + trametinib(MEK inhibitor) *** (carboplatin + paclitaxel) or paclitaxel or dacabazine or temozolomide

More Related